- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02312869
Local Assessment of Management of Burn Patients (LAMiNAR)
Local Assessment of Management of Burn Patients (LAMiNAR) - a Prospective Observational International Multicenter Cohort Study
In the general intensive care unit (ICU) population, there is strong evidence for benefit from lung-protective mechanical ventilation, including the use of low tidal volumes and adequate levels of positive end-expiratory pressure (PEEP). In burn patients it is highly uncertain whether these settings are beneficial and there are even concerns over safety of, in particular use of low tidal volumes. There is lack of international guidelines and consequently ventilation practice in burn patients may widely vary.
The primary objective is to determine ventilation practice in burn ICUs worldwide, focusing on the size of tidal volumes and the levels of PEEP used for burn patients. In addition, data on other strategies considered important in patients who receive ventilation are also collected, including data on neuromuscular blocking agents, sedatives and analgesics, and type and amount of intravenous fluids used in the period of ventilation. The secondary objective is to determine the association between tidal volume size and levels of PEEP, and duration of ventilation in burn patients.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patient population: Consecutive burn patients admitted to participating burn ICUs who receive invasive ventilation, irrespective of severity of burn injury and/or presence of inhalation trauma are eligible for participation.
Data collection: includes burn patients admitted within a period of three months. Demographic and baseline data are collected from the clinical files on the day of admission. If available, standard of care and clinical outcome parameters are collected daily until day 14, death or discharge from ICU, whatever comes first.
Sample size: The primary objective is to determine (variations in) ventilation practice in burn patients in burn ICUs. Therefore, the sample size is based on the main secondary objective, which is to determine the association between the following ventilator settings: tidal volume, PEEP, FiO2 and mode; and outcome of burn patients. The investigators calculated the sample size for a multiple regression model: a sample size of at least 300 patients is required to have a power of 0.80, a significance level of 0.05, using an estimated effect size of 0.04, while using 4 independent variables in the model.
Ethics Approval: National coordinators will be responsible for clarifying the need for ethics approval and applying for this where appropriate according to local policy. Centres will not be permitted to record data unless ethics approval or an equivalent waiver is in place. The investigators expect that in most, if not every participating country, a patient informed consent is not be required.
Monitoring: Due to the observational nature of the study, a DSMB is not necessary.
Organization: National co-ordinators will lead the project within individual nations and identify participating hospitals, translate study paperwork, distribute study paperwork and ensure necessary regulatory approvals are in place. They provide assistance to the participating clinical sites in trial management, record keeping and data management. Local coordinators in each site will supervise data collection and ensure adherence to Good Clinical Practice during the trial.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Zuid Holland
-
Amsterdam, Zuid Holland, Netherlands, 1105AZ
- Academic Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Burns
- Admission to a participating burn ICU Need for invasive ventilation
- Informed consent (only if applicable in the country where data are collected)
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ventilation parameters
Time Frame: Up to 14 days during mechanical ventilation
|
Tidal volume size; milliliters per kilogram of predicted body weight
|
Up to 14 days during mechanical ventilation
|
Ventilation parameters
Time Frame: Up to 14 days during mechanical ventilation
|
Level of positive end-expiratory pressure (PEEP); cm H2O
|
Up to 14 days during mechanical ventilation
|
Ventilation parameters
Time Frame: Up to 14 days during mechanical ventilation
|
Fraction of oxygen in inspired air (FiO2), %
|
Up to 14 days during mechanical ventilation
|
Ventilation parameters
Time Frame: Up to 14 days during mechanical ventilation
|
Mode of ventilation; assist-control or spontaneous modes of ventilation
|
Up to 14 days during mechanical ventilation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Length of Stay in ICU on Day 90
Time Frame: Until day 90
|
Time between admission and discharge or death
|
Until day 90
|
Length of Stay in Hospital on Day 90
Time Frame: Until day 90
|
Time between admission and discharge or death
|
Until day 90
|
All-cause ICU Mortality
Time Frame: Until day 90
|
Any death during ICU stay
|
Until day 90
|
All-cause Hospital Mortality
Time Frame: Until day 90
|
Any death during hospital stay
|
Until day 90
|
Number of ventilator-free days and alive at day 28
Time Frame: From day 1 to day 28
|
Defined as the number of days, from day 1 to day 28, the patient is alive and breathes without assistance of a mechanical ventilator, if the period of unassisted breathing lasted at least 24 consecutive hours.
Notably, if after successful withdrawal of mechanical ventilation the patient requires ventilation for a surgical procedure, this will not count as a 'ventilator day'.
If ventilation is prolonged after surgery due to respiratory insufficiency, the day(s) ventilation is required counts as a 'ventilator day'
|
From day 1 to day 28
|
Other Ventilation Parameters
Time Frame: Up to 14 days during mechanical ventilation
|
Peak and plateau pressures or maximum airway pressure
|
Up to 14 days during mechanical ventilation
|
Other Ventilation Parameters
Time Frame: Up to 14 days during mechanical ventilation
|
Respiratory rate
|
Up to 14 days during mechanical ventilation
|
Other Ventilation Parameters
Time Frame: Up to 14 days during mechanical ventilation
|
Inspiration to expiration ratio
|
Up to 14 days during mechanical ventilation
|
Other Ventilation Parameters
Time Frame: Up to 14 days during mechanical ventilation
|
Peripheral oxygen saturation
|
Up to 14 days during mechanical ventilation
|
Other Ventilation Parameters
Time Frame: Up to 14 days during mechanical ventilation
|
Arterial blood gas parameters
|
Up to 14 days during mechanical ventilation
|
Need for Tracheostomy
Time Frame: daily up to 14 days from inclusion
|
Need for tracheostomy, first tracheostomy will be assessed up to 14 days from inclusion
|
daily up to 14 days from inclusion
|
Daily Lung Injury Scores
Time Frame: Up to 14 days during mechanical ventilation
|
Score based on chest X-ray findings (if obtained), PaO2/FiO2, PEEP level and respiratory compliance.
|
Up to 14 days during mechanical ventilation
|
Daily Sequential Organ Failure Assessment (SOFA)-scores
Time Frame: Daily up to 14 days from inclusion
|
six-organ dysfunction/failure score measuring multiple organ failure daily
|
Daily up to 14 days from inclusion
|
Complications
Time Frame: Daily up to 14 days from inclusion
|
Complications will include: Skin and soft tissue infections
|
Daily up to 14 days from inclusion
|
Complications
Time Frame: Daily up to 14 days from inclusion
|
Complications will include: (Ventilator associated) Pneumonia
|
Daily up to 14 days from inclusion
|
Complications
Time Frame: Daily up to 14 days from inclusion
|
Complications will include: Sepsis
|
Daily up to 14 days from inclusion
|
Complications
Time Frame: Daily up to 14 days from inclusion
|
Complications will include: Acute respiratory distress syndrome according to Berlin criteria
|
Daily up to 14 days from inclusion
|
Complications
Time Frame: Daily up to 14 days from inclusion
|
Complications will include: Acute renal failure
|
Daily up to 14 days from inclusion
|
Complications
Time Frame: Daily up to 14 days from inclusion
|
Complications will include: Abdominal compartment syndrome
|
Daily up to 14 days from inclusion
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Standard care strategies
Time Frame: Daily up to 14 days from inclusion
|
Strategies considered to be important in patients who receive ventilation, including: Fluid balance, types and dose of fluids used
|
Daily up to 14 days from inclusion
|
Standard care strategies
Time Frame: Daily up to 14 days from inclusion
|
Strategies considered to be important in patients who receive ventilation, including: use of sedative and analgesic drugs
|
Daily up to 14 days from inclusion
|
Standard care strategies
Time Frame: Daily up to 14 days from inclusion
|
Strategies considered to be important in patients who receive ventilation, including: use of sedation and delirium scores
|
Daily up to 14 days from inclusion
|
Standard care strategies
Time Frame: Daily up to 14 days from inclusion
|
Strategies considered to be important in patients who receive ventilation, including: use of neuromuscular blocking agents
|
Daily up to 14 days from inclusion
|
Standard care strategies
Time Frame: Daily up to 14 days from inclusion
|
Strategies considered to be important in patients who receive ventilation, including: use of antibiotic prophylaxis
|
Daily up to 14 days from inclusion
|
Collaborators and Investigators
Investigators
- Principal Investigator: Marcus J. Schultz, MD, PhD, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LAMiNAR
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mechanical Ventilation
-
Thammasat UniversityCompletedProlonged Mechanical Ventilation | Home Mechanical VentilationThailand
-
JOSE IVAN RODRIGUEZ DE MOLINA SERRANOCompletedMechanical Ventilation Complication | Mechanical Power | Driving Pressure | Lung Protective VentilationMexico
-
Academisch Medisch Centrum - Universiteit van Amsterdam...University of Zurich; Dijklander Ziekenhuis; Reinier de Graaf GroepCompletedMechanical Ventilation | Mechanical PowerNetherlands
-
Rabin Medical CenterUnknownMechanical Ventilation | Weaning | Prolonged Ventilation
-
Drägerwerk AG & Co. KGaAUniversity of Göttingen; Prof. Dr. med. ImhoffSuspendedMechanical Ventilation | Ventilation Perfusion MismatchGermany
-
Capital Medical UniversityRecruitingMechanical VentilationChina
-
University of ChicagoActive, not recruitingMechanical VentilationUnited States
-
Chang Gung UniversityCompleted
-
The University of Texas Health Science Center,...Edwards LifesciencesWithdrawnMechanical VentilationUnited States
-
Bursa Yüksek İhtisas Education and Research HospitalCompletedthe Effect of Different Mechanical Ventilation Modes on Optic Nerve Diameter and Conscious FunctionsMechanical VentilationTurkey
Clinical Trials on No intervention
-
Wave NeuroscienceCompletedAutistic DisorderUnited States
-
University of Alabama at BirminghamCompletedInflammatory Bowel Diseases | Colorectal Cancer | Diverticular Diseases | Social BehaviorUnited States
-
Janssen Research & Development, LLCCompletedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, DiscoidUnited States, Poland
-
Hospital Universitario La Paz3MVX CCB and Agaplesion Markus Krankenhaus, Frankfurt a.M., Germany.; Department...RecruitingEmbolism | Atrial Fibrillation | Arrhythmia | Stroke, Acute | Stroke Sequelae | AblationSpain
-
Southern California College of Optometry at Marshall...Ohio State University; University of Houston; Alcon Research; University of Waterloo and other collaboratorsCompletedContact Lens Complication | Contact Lens Acute Red Eye | Contact Lens Related Corneal Infiltrate (Disorder) | Contact Lens-Induced Corneal Fluorescein StainingUnited States, Canada
-
University of Dublin, Trinity CollegeCompleted
-
Hôpital Necker-Enfants MaladesUnknown
-
China Medical University HospitalUnknownIntention to Stay, Turnover Behavior
-
University of PittsburghCompletedChronic Low Back PainUnited States